Skip to main content
Top
Published in: Journal of General Internal Medicine 7/2014

01-07-2014 | Original Research

Comparative-Effectiveness of Revascularization Versus Routine Medical Therapy for Stable Ischemic Heart Disease: A Population-Based Study

Authors: Harindra C. Wijeysundera, MD, PhD, Maria C. Bennell, MSc, MPH, Feng Qiu, MSc, Dennis T. Ko, MD, MSc, Jack V. Tu, MD, PhD, Duminda N. Wijeysundera, MD, PhD, Peter C. Austin, PhD

Published in: Journal of General Internal Medicine | Issue 7/2014

Login to get access

ABSTRACT

BACKGROUND

Randomized studies have shown optimal medical therapy to be as efficacious as revascularization in stable ischemic heart disease (IHD). It is not known if these efficacy results are reflected by real-world effectiveness.

OBJECTIVE

To evaluate the comparative effectiveness of routine medical therapy versus revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in stable IHD.

DESIGN

Observational cohort study.

PATIENTS

Stable IHD patients from 1 October 2008 to 30 September 2011, identified using a Registry of all angiography patients in Ontario, Canada.

INTERVENTION

Revascularization, defined as PCI/CABG within 90 days after index angiography.

MAIN MEASURES

Death, myocardial infarction (MI) or repeat PCI/CABG. Revascularization was compared to medical therapy using a) multivariable Cox-proportional hazard models with therapy strategy treated as a time-varying covariate; and b) a propensity score matched analysis. Post-angiography medication use was determined.

KEY RESULTS

We identified 39,131 stable IHD patients, of whom 15,139 were treated medically, and 23,992 were revascularized (PCI = 15,604; CABG = 8,388). Mean follow-up was 2.5 years. Revascularization was associated with fewer deaths (HR 0.76; 95 % CI 0.68–0.84; p < 0.001) ,MIs (HR 0.78; 95 % CI 0.72–0.85; p < 0.001) and repeat PCI/CABG (HR 0.59; 95 % CI 0.50–0.70; p < 0.001) than medical therapy. In the propensity-matched analysis of 12,362 well–matched pairs of revascularized and medical therapy patients, fewer deaths (8.6 % vs 12.7 %; HR 0.75; 95 % CI 0.69–0.81; p < 0.001) , MIs (11.7 % vs 14.4 %; HR 0.84; 95 % CI 0.77–0.93 p < 0.001) and repeat PCI/CABG ( 17.4 % vs 24.1 %;HR 0.67; 95 % 0.63–0.71; p < 0.001) occurred in revascularized patients, over the 4.1 years of follow-up.
The revascularization patients had higher uptake of clopidogrel (70.3 % vs 27.2 %; p < 0.001), β-blockers (78.2 % vs 76.7 %; p = 0.010), and statins (94.7 % vs 91.5 %, p < 0.001) in the 1-year post-angiogram.

CONCLUSIONS

Stable IHD patients treated with revascularization had improved risk-adjusted outcomes in clinical practice, potentially due to under-treatment of medical therapy patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264–74.PubMedCrossRef Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264–74.PubMedCrossRef
2.
go back to reference Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.PubMedCrossRef Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.PubMedCrossRef
3.
go back to reference Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373(9667):911–8.PubMedCentralPubMedCrossRef Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373(9667):911–8.PubMedCentralPubMedCrossRef
4.
go back to reference Group BDS, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRef Group BDS, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRef
5.
go back to reference Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O’Neill WW, et al. The Truth and Consequences of the COURAGE Trial. J Am Coll Cardiol. 2007;50(16):1598–603.PubMedCrossRef Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O’Neill WW, et al. The Truth and Consequences of the COURAGE Trial. J Am Coll Cardiol. 2007;50(16):1598–603.PubMedCrossRef
7.
go back to reference Cardiac Care Network (CCN) Annual Report 2010/2011. 2011. Cardiac Care Network (CCN) Annual Report 2010/2011. 2011.
8.
go back to reference Tu JV, Ko DT, Guo H, Richards JA, Walton N, Natarajan MK, et al. Determinants of variations in coronary revascularization practices. CMAJ. 2011. Tu JV, Ko DT, Guo H, Richards JA, Walton N, Natarajan MK, et al. Determinants of variations in coronary revascularization practices. CMAJ. 2011.
9.
go back to reference Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67–71.PubMed Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67–71.PubMed
10.
go back to reference Ko DT, Newman AM, Alter DA, Austin PC, Chiu M, Cox JL, et al. Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. Can J Cardiol. 2010;26(3):129–34.PubMedCentralPubMedCrossRef Ko DT, Newman AM, Alter DA, Austin PC, Chiu M, Cox JL, et al. Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. Can J Cardiol. 2010;26(3):129–34.PubMedCentralPubMedCrossRef
11.
go back to reference Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.PubMedCrossRef Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.PubMedCrossRef
12.
go back to reference Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399–424.PubMedCentralPubMedCrossRef Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399–424.PubMedCentralPubMedCrossRef
13.
go back to reference Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010.
14.
go back to reference Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.PubMedCentralPubMedCrossRef Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.PubMedCentralPubMedCrossRef
15.
go back to reference Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292–301.PubMedCentralPubMed Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292–301.PubMedCentralPubMed
16.
go back to reference Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41(1):56–61.PubMedCrossRef Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41(1):56–61.PubMedCrossRef
17.
go back to reference Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA. 2010;303(18):1841–7.PubMedCrossRef Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA. 2010;303(18):1841–7.PubMedCrossRef
18.
go back to reference Wijeysundera HC, Mitsakakis N, Witteman W, Paulden M, van der Velde G, Tu JV, et al. Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality. Can J Cardiol. 2011;27(6):756–62.PubMedCrossRef Wijeysundera HC, Mitsakakis N, Witteman W, Paulden M, van der Velde G, Tu JV, et al. Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality. Can J Cardiol. 2011;27(6):756–62.PubMedCrossRef
19.
go back to reference Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882–9.PubMedCrossRef Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882–9.PubMedCrossRef
20.
go back to reference Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.PubMedCrossRef Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.PubMedCrossRef
21.
go back to reference Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. [Review] [114 refs]. Lancet. 2006;367(9504):69–78.PubMedCrossRef Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. [Review] [114 refs]. Lancet. 2006;367(9504):69–78.PubMedCrossRef
22.
go back to reference Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP, et al. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007;99(9):1212–5.PubMedCrossRef Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP, et al. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007;99(9):1212–5.PubMedCrossRef
23.
go back to reference American College of Cardiology, American Heart Association, Physician Consortium for Performance ImprovementClinical Performance Measures: Chronic Stable Coronary Artery Disease. . 2003. American College of Cardiology, American Heart Association, Physician Consortium for Performance ImprovementClinical Performance Measures: Chronic Stable Coronary Artery Disease. . 2003.
24.
go back to reference Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation. 2012;125(15):1870–9.PubMedCrossRef Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation. 2012;125(15):1870–9.PubMedCrossRef
25.
go back to reference Muhlbaier LH, Pryor DB, Rankin JS, Smith LR, Mark DB, Jones RH, et al. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-up. Circulation. 1992;86(5 Suppl):II198–204.PubMed Muhlbaier LH, Pryor DB, Rankin JS, Smith LR, Mark DB, Jones RH, et al. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-up. Circulation. 1992;86(5 Suppl):II198–204.PubMed
Metadata
Title
Comparative-Effectiveness of Revascularization Versus Routine Medical Therapy for Stable Ischemic Heart Disease: A Population-Based Study
Authors
Harindra C. Wijeysundera, MD, PhD
Maria C. Bennell, MSc, MPH
Feng Qiu, MSc
Dennis T. Ko, MD, MSc
Jack V. Tu, MD, PhD
Duminda N. Wijeysundera, MD, PhD
Peter C. Austin, PhD
Publication date
01-07-2014
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 7/2014
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-014-2813-1

Other articles of this Issue 7/2014

Journal of General Internal Medicine 7/2014 Go to the issue

Clinical Practice: Exercises in Clinical Reasoning

A 22-Year-Old Woman with Abdominal Pain

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.